Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease
Journal of Nuclear Medicine · 2023
DOI: 10.2967/jnumed.123.265649 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2023. Verfasst von Farzaneh Rezazadeh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Colitis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD), which includes both Crohn disease and ulcerative colitis, is a relapsing inflammatory disease of the gastrointestinal tract. Long-term chronic inflammatory conditions elevate the patient's risk of colorectal cancer (CRC). Currently, diagnosis requires endoscopy with biopsy. This procedure is invasive and requires a bowel-preparatory regimen, adding to patient burden. Interleukin 12 (IL12) and interleukin 23 (IL23) play key roles in inflammation, especially in the pathogenesis of IBD, and are established therapeutic targets. We propose that imaging of IL12/23 and its p40 subunit in IBD via immuno-PET potentially provides a new noninvasive diagnostic approach.
Methods
Our aim was to investigate the potential of immuno-PET to image inflammation in a chemically induced mouse model of colitis using dextran sodium sulfate by targeting IL12/23p40 with a 89Zr-radiolabeled anti-IL12/23p40 antibody.
Results
High uptake of the IL12/23p40 immuno-PET agent was exhibited by dextran sodium sulfate-administered mice, and this uptake correlated with increased IL12/23p40 present in the sera. Competitive binding studies confirmed the specificity of the radiotracer for IL12/23p40 in the gastrointestinal tract.
Conclusion
These promising results demonstrate the utility of this radiotracer as an imaging biomarker of IBD. Moreover, IL12/23p40 immuno-PET can potentially guide treatment decisions for IBD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
- Departments of Obstetrics and Gynecology, Wayne State University, Detroit, Michigan.
- Department of Gastroenterology, Wayne State University, Detroit, Michigan; and.
- Department of Anatomic Pathology, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan.
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan; violan@karmanos.org.
Förderung
- NCI NIH HHS
Zitieren
APA
Rezazadeh, F., Ramos, N., Saliganan, A. D., Al-Hallak, N., Chen, K., Mohamad, B., Wiesend, W. N., & Viola, N. T. (2023). Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.265649
Vancouver
Rezazadeh F, Ramos N, Saliganan AD, Al-Hallak N, Chen K, Mohamad B, et al. Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease. Journal of Nuclear Medicine. 2023. doi:10.2967/jnumed.123.265649
BibTeX
@article{Rezazadeh2023,
author = {Rezazadeh, Farzaneh and Ramos, Nicholas and Saliganan, Allen-Dexter and Al-Hallak, Najeeb and Chen, Kang and Mohamad, Bashar and Wiesend, Wendy N and Viola, Nerissa T},
title = {Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease},
journal = {Journal of Nuclear Medicine},
year = {2023},
doi = {10.2967/jnumed.123.265649}
}
EUVIMED